ERBB2 and breast cancer: The differences in frequency of TP53 mutation, and clinical characteristics such as lack of TP53 enrichment at very early onset (≤ 30 years of age) BC and the lack of association with HER2 status further suggest that TP53 carriers may vary across different ethnicities and countries.